Dr. Brent Reynolds is an internationally recognized expert in neural stem cell biology and brain tumor research, with a long-standing focus on translating basic science discoveries into therapeutic strategies for malignant brain tumors. As a Scientific Advisor to Immunogenik, Dr. Reynolds provides expert guidance on tumor biology, preclinical modeling, and translational strategy—particularly for central nervous system (CNS) malignancies.

A professor in the Department of Neurosurgery at the University of Florida, Dr. Reynolds has spent over two decades advancing the understanding of neural stem cells and their role in glioma biology. His lab pioneered the development of patient-derived stem-like tumor models that faithfully recapitulate the heterogeneity and microenvironment of human brain cancers, tools that are now widely used to evaluate novel therapeutic candidates.

Dr. Reynolds also brings extensive experience in biotechnology translation and startup development. He has co-founded multiple biotech ventures and led preclinical efforts that progressed into clinical trials. His deep knowledge of brain tumor pathophysiology, combined with a practical understanding of the translational pathway, allows him to advise Immunogenik on both scientific and strategic dimensions of product development.

At Immunogenik, Dr. Reynolds contributes to the refinement of therapeutic hypotheses, selection of relevant in vivo models, and the design of robust translational studies that bridge bench science with clinical application—especially in glioblastoma and pediatric high-grade glioma.